Martin Mackay

  • Co-founder, chair of the Board, CEO and holder of an executive leadership role overseeing all research and non-research functions, Rallybio LLC.
  • Senior advisor to New Leaf Venture Partners, LLC.
  • Member of the board of 5:01 Acquisition Corporation.
  • Member of the board and chair of the Science and Technology Committee of Charles River Laboratories International, Inc.

  • President of Global Research and Development at AstraZeneca plc., 2010-2013.
  • President and senior vice president within Research and Development, and other roles, Pfizer, Inc., 1995-2010.
  • Visiting professor at the Department of Pharmacy at King’s College, London, 1998-2006 and at the Department of Biomedical Sciences at the University of Lincoln, 1998-2014.

  • Considered independent under the Danish Recommendations on Corporate Governance.
  • Member of the Board of Directors since March 2018. Most recently elected in 2021 for a term of one year.
  • Chair of the Research & Development Committee since March 2018.
  • Member of the Remuneration Committee since March 2021.

  • Global corporate leadership
  • Healthcare and pharma industry
  • Medicine & science
  • Technology
  • Business development, M&A and external innovation sourcing
  • Human capital management

  • 1984: Doctorate/PhD, University of Edinburgh, UK.
  • 1979: BSc (First Class Honours) in Microbiology, Heriot-Watt University, Edinburgh, UK.

US national, born 1956. Male.